via European Pharmaceutical Review
Inserting genetic material into the body to treat diseases caused by gene mutations can work, scientists say – but getting those materials to the right place safely is tricky.
Scientists report today (Aug. 21) in the journal Science Advances that the lipid-based nanoparticles they engineered, carrying two sets of protein-making instructions, showed in animal studies that they have the potential to function as therapies for two genetic disorders.
In one experiment, the payload-containing nanoparticles prompted the production of the missing clotting protein in mice that are models for hemophilia. In another test, the nanoparticles’ cargo reduced the activation level of a gene that, when overactive, interferes with clearance of cholesterol from the bloodstream.
Each nanoparticle contained an applicable messenger RNA – molecules that translate genetic information into functional proteins.
“We demonstrated two applications for lipid-like nanomaterials that effectively deliver their cargo, appropriately biodegrade and are well-tolerated,” said Yizhou Dong, senior author of the study and associate professor of pharmaceutics and pharmacology at The Ohio State University.
“With this work, we have lowered potential side effects and toxicity, and have broadened the therapeutic window. This gives us confidence to pursue studies in larger animal models and future clinical trials.”
This work builds upon a collection of lipid-like spherical compounds that Dong and colleagues had previously developed to deliver messenger RNA. This line of particles was designed to target disorders involving genes that are expressed in the liver.
The team experimented with various structural changes to those particles, effectively adding “tails” of different types of molecules to them, before landing on the structure that made the materials the most stable. The tiny compounds have a big job to do: embarking on a journey through the bloodstream, carrying molecules to the target location, releasing the ideal concentration of messenger RNA cargo at precisely the right time and safely degrading.
The tests in mice suggested these particles could do just that.
The researchers injected nanoparticles containing messenger RNA holding the instructions to produce a protein called human factor VIII into the bloodstream of normal mice and mouse models for hemophilia. A deficiency of this protein, which enables blood to clot, causes the bleeding disorder. Within 12 hours, the deficient mice produced enough human factor VIII to reach 90 percent of normal activity. A check of the organs of both protein-deficient mice and normal mice showed that the treatment caused no organ damage.
“It can be helpful to think of this as a protein-replacement therapy,” Dong said.
In the second experiment, nanomaterials were loaded with two types of instructions: messenger RNA carrying the genetic code for a DNA base editor, and a guide RNA to make sure the edits occurred in a specific gene in the liver called PCSK9. Dozens of mutations that increase this gene’s activity are known to cause high cholesterol by reducing clearance of cholesterol from the bloodstream.
Analyses showed that the treatment resulted in the intended mutation of about 60 percent of the target base pairs in the PCSK9 gene, and determined that only a low dose was needed to produce high editing effect.
Dong credited academic and industry partners for helping advance this work. Co-corresponding authors include Denise Sabatino of Children’s Hospital of Philadelphia and Delai Chen from Boston-based Beam Therapeutics, who provided expertise in hemophilia and DNA base editing, respectively.
Dong and first author Xinfu Zhang are inventors on patent applications filed by Ohio State related to the lipid-like nanoparticles. This technology has been licensed for further clinical development.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Protein-replacement therapy
- The Beam: Proton therapy conference recap, your protein needs during therapy, meet Jillian Wimbery
What's new in Proton Therapy? Read the latest news and views from Fred Hutch's Proton Therapy facility, patients and providers in The Beam, published monthly.
- From Theory to Therapy: MIT’s Computational Breakthrough in Protein Optimization
MIT researchers plan to search for proteins that could be used to measure electrical activity in the brain. To engineer proteins with useful functions, researchers usually begin with a natural protein ...
- Dementia in Children: Unlocking Hope with Novel Research
Although the causes differ from dementia acquired later in life, the progressive nature of the illness is the same.Half of infants and children diagnosed with childhood dementia will not reach their ...
- US FDA approves Pfizer's gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a ...
- US Approves Gene Therapy Treatment For Hemophilia
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday.
Go deeper with Google Headlines on:
Protein-replacement therapy
[google_news title=”” keyword=”protein-replacement therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Engineered therapeutic delivery system
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
This announcement represents a renewed opportunity to advance curative genetic medicine through the translation of Metagenomi’s broad toolbox of wholly-owned gene editing technologies, as well as a ...
- Researchers discover key functions of therapeutically promising jumbo viruses
Antibiotic medicines became a popular treatment for bacterial infections in the early 20th century and emerged as a transformational tool in human health. Through the middle of the century, novel ...
- Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meeting
The Company will also share new preclinical NHP data demonstrating functional delivery of genome editors to the retina and supporting therapeutic use ... ARMMs were discovered and engineered into a ...
- Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C. and SEATTLE, May 01, 2024 (GLOBE NEWSWIRE) -- Creyon Bio, Inc. ('Creyon'), a drug development ...
- Short electric pulses show promise for enhancing gene therapy
Electrical engineering researchers at the University of Wisconsin–Madison have developed a stimulating method that could make the human body more receptive to certain gene therapies.
Go deeper with Google Headlines on:
Engineered therapeutic delivery system
[google_news title=”” keyword=”engineered therapeutic delivery system” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]